[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355999-105":59,"doc-detail-355999-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","osteopontin-mediates-acquired-resistance-to-hypoxiainducing-antiangiogenics-and-promotes-anti-pd-l1-refractoriness-in-breast-cancer-models","Osteopontin mediates acquired resistance to hypoxiainducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models","","Resistance to antiangiogenic cancer therapy remains poorly understood, particularly when treatment drives persistent hypoxia. Integrating mouse models and clinical-trial data, the study shows that hypoxia-inducing anti-VEGF upregulates PD-L1 while failing to sensitize tumors to PD-L1 blockade. Early hypoxic stress induces epithelial osteopontin (SPP1), recruiting monocytes and polarizing macrophages to M2 states that suppress T cell cytotoxicity. Pharmacologic or genetic SPP1 depletion reduces hypoxia and M2 infiltration, restores T cell function, and enables antiangiogenic–anti–PD-L1 synergy, identifying SPP1 as a central mediator and a target for personalized immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/osteopontin-mediates-acquired-resistance-to-hypoxiainducing-antiangiogenics-and-promotes-anti-pd-l1-refractoriness-in-breast-cancer-models/355999/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/osteopontin-mediates-acquired-resistance-to-hypoxiainducing-antiangiogenics-and-promotes-anti-pd-l1-refractoriness-in-breast-cancer-models/355999.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does hypoxia-inducing anti-VEGF therapy affect PD-L1 expression and treatment response?","Question",{"text":112,"@type":113},"It upregulates PD-L1 but does not sensitize tumors to PD-L1 blockade, leaving tumors resistant despite PD-L1 induction.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does osteopontin (SPP1) play in resistance to antiangiogenic therapy under hypoxic conditions?",{"text":117,"@type":113},"Early hypoxic stress triggers epithelial SPP1 production, which recruits monocytes and skews macrophages toward M2-like immune-suppressive states, suppressing T cell cytotoxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens when SPP1 is depleted pharmacologically or genetically?",{"text":121,"@type":113},"SPP1 depletion impedes hypoxia development, reduces M2 infiltration, restores T cell activity, and enables synergy between antiangiogenics and anti–PD-L1 therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355999,1790188992,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nOsteopontin mediates acquired resistance to hypoxiainducing antiangiogenics and promotes anti–PD-L1 refractoriness in breast cancer models  \nJose Luis Ruiz-Sepulveda,1 Maria J. Bueno,1 Silvana Mouron,1 Veronica Jimenez-Renard,1 Manuel Muñoz,1 Manuel Moradiellos,2 Leonardo D. Garma,1 Luis García-Jimeno,2 Adam W. Watson,3 Ghassan Mouneimne,3,4 Solip Park,2 Rebeca Jimeno,1,5 and Miguel Quintela-Fandino1,6,7  \n1Breast Cancer Clinical Research Unit and 2Computational Cancer Genomics Group, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain. 3MeCo Diagnostics Holdings, Inc., San Diego, California, USA. 4University of Arizona Cancer Center, Tucson, Arizona, USA. 5Centro de Biología Molecular Severo Ochoa–CSIC, Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain. 6Endowed Chair of Personalized Precision Medicine, Universidad Autónoma de Madrid– Fundación Instituto Roche, Madrid, Spain. 7Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain.  \nResistance to antiangiogenics is a major challenge in cancer therapy. These agents can either normalize or exacerbate tumor vascular abnormality and hypoxia. The mechanisms of resistance remain unclear in the latter setting. By integrating data from mouse models and clinical trials, we showed that hypoxia-inducing anti-VEGF therapy upregulated programmed cell death ligand 1 (PD-L1), yet failed to sensitize tumors to PD-L1 blockade. Mechanistically, early hypoxic stress triggered epithelial osteopontin (SPP1) production, which recruited monocytes and skewed macrophages toward M2 states, suppressing T cell cytotoxicity. Pharmacological SPP1 depletion impeded the development of hypoxia, reduced M2 infiltration, restored T cell activity, and enabled synergy between antiangiogenics and anti–PD-L1 . Genetic dissection —tumor-epithelial Spp1-KO grafts and bone marrow chimeras generated by lethal irradiation and reconstitution with Spp1–/– or WT hematopoietic donors — showed that myeloid SPP1 contributed only marginally compared with epithelial SPP1 .  \nThese findings identified SPP1 as a central mediator of resistance to hypoxia-inducing antiangiogenics, contributed to a comprehensive model of antiangiogenic resistance, and supported SPP1-targeted strategies to personalize immunotherapy and antiangiogenic therapy according to tumor hypoxia.  \nIntroduction  \nTumor vasculature is abnormal because of an imbalance between pro- and antiangiogenic signals, which sustains hypoxia and other protumorigenic features (1) . Antiangiogenic therapy can transientlyrestore this balance and normalize the vasculature, thereby improving drug delivery and delaying progression (1) . In breast cancer, this translated into consistent improvements in progression-free survival, but not in overall survival (OS), highlighting the lack of biomarkers able to identify the patients and treatment contexts most likely to benefit (2–5) . We and others have shown that antiangiogenic exposure does not produce a uniform vascular response: tumors may either normalize or become more abnormal and hypoxic, even within the same histologic setting and after treatment with the same drug (6–9) . This divergence, given the profound implications of hypoxia in tumor biology, is likely to condition subsequent adaptation to therapy.  \nWe previously investigated resistance after vascular normalization and found in preclinical models that a shift from glycolysis to mitochondrial respiration sustained tumor growth in that setting  \nAuthorship note: RJ and MQF contributed equally to this work.  \nCopyright: © 2026, Ruiz-Sepulveda et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Submitted: February 1, 2024; Accepted: May 28, 2026; Published: July 15, 2026.  \nReference information: J Clin Invest. 2026;136(14):e174092 .  \n[https://doi.org/10.1172/JCI174092](https://doi.org/10.1172/","cbCaio1EODNrwVt9","https://ap.wps.com/l/cbCaio1EODNrwVt9","pdf",10814893,17,"English","# Introduction\n## Tumor hypoxia and antiangiogenic therapy responses\n# Results\n## Hypoxia-inducing antiangiogenic treatment and PD-1/PD-L1 blockade efficacy","[{\"question\":\"How does hypoxia-inducing anti-VEGF therapy affect PD-L1 expression and treatment response?\",\"answer\":\"It upregulates PD-L1 but does not sensitize tumors to PD-L1 blockade, leaving tumors resistant despite PD-L1 induction.\"},{\"question\":\"What role does osteopontin (SPP1) play in resistance to antiangiogenic therapy under hypoxic conditions?\",\"answer\":\"Early hypoxic stress triggers epithelial SPP1 production, which recruits monocytes and skews macrophages toward M2-like immune-suppressive states, suppressing T cell cytotoxicity.\"},{\"question\":\"What happens when SPP1 is depleted pharmacologically or genetically?\",\"answer\":\"SPP1 depletion impedes hypoxia development, reduces M2 infiltration, restores T cell activity, and enables synergy between antiangiogenics and anti–PD-L1 therapy.\"}]","Osteopontin mediates acquired resistance to hypoxiainducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models | PDF",1790122236,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0847e673f7304e164690d1589f9e9e6e.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7714ece885e96c4bfcd3bc702a8d6994.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f67dc8d5dc466660ae9525d786a453ce.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d8678bbce1a7d3e8702129cfa24e19a.webp",980,1311]